Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

HSBC on Monday double downgraded Eli Lilly and Co. (LLY) stock to ‘Reduce’ from ‘Buy’ and also lowered its price target to ...

Neoadjuvant PD-1 blockade in dMMR tumors "could potentially eradicate the need for chemotherapy, radiation, and surgery in ...

As the tariff wars continue to unfold, the markets are attempting to kick off the week with gains as the latest slew of tech ...

IBM is making a major bet on America's tech future. The company announced plans on Monday to invest $150 billion across the ...

IBM unveiled a $150 billion plan to invest in the U.S., adding to a series of commitments by big corporations. Here's a rundown of some of the multibillion-dollar pledges made since President Trump to ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

Weight loss drugs like Ozempic, Zepbound and Wegovy are surging in popularity. Now, a new pill from Eli Lilly has taken a ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

With its 2-star rating, we believe Lilly stock is overvalued compared with our long-term fair value estimate of $650 per ...

Top US firms are boosting executive security spending after the killing of UnitedHealth’s Brian Thompson, with costs expected ...

Many of the world's biggest companies are sitting on millions -- sometimes hundreds of millions -- of dollars in unused or ...